About Vitaeris
Vitaeris is a company based in Vancouver (Canada) founded in 2016 was acquired by CSL Behring in June 2020. Vitaeris has raised $7 million across 1 funding round from investors including HBM Healthcare Investments and CSL Behring. Vitaeris operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Alexion, among others.
- Headquarter Vancouver, Canada
- SectorsHealthcare
- Email••••••••
- Website vitaerisbio.com
- Social LinkedIn X
- Acquired by CSL Behring (Jun 2020)
- Total Equity Funding$7M (USD)
in 1 rounds
- Latest Funding Round$7M (USD), Seed
Jun 2016
- InvestorsHBM Healthcare Investments
& 1 more
- Acquired byCSL Behring
(Jun 2020)
Funding Insights of Vitaeris
Vitaeris has successfully raised a total of $7M through 1 strategic funding round. The most recent funding activity was a Seed round of $7 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7M
- Total Rounds 1
- Last Round Seed — $7M
- First Round $7M
(Jun 2016)
- Investors Count 1
All 1 funding rounds of Vitaeris with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $7M | Seed | – | HBM Healthcare Investments | – |
2 investors in total: 2 institutional.
Investors in Vitaeris
Vitaeris has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include HBM Healthcare Investments and CSL Behring.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Developer of therapeutic solutions for the treatment of coagulation disorder | 2009 | cslbehring.com | King Of Prussia, United States |
Investor details for Vitaeris
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Vitaeris
3 dated milestones of Vitaeris across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Vitaeris is founded.
- Funding First funding round of $7.0M.
- Exit Acquired by CSL Behring.
Competitors of Vitaeris
Vitaeris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Alexion, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| alexion.com | 1992 | Zurich, Switzerland | $8M | 1 | Therapies for rare and devastating diseases are developed by Alexion. | |
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | – | Antibody therapies are developed through machine learning and synthetic biology. | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| kodiak.com | 2009 | Palo Alto, United States | $35.84M | 112 | Therapeutics for retinal diseases are developed by the company. |
Detailed competitors of Vitaeris
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vitaeris
Complete news archive for Vitaeris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Vitaeris
10 companies that operate in the same segment as Vitaeris (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vitaeris
Vitaeris was founded in 2016.
Vitaeris is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Vitaeris is a funded company, having raised a total of $7M across 1 funding round to date. The company's 1st funding round was a Seed of $7M, raised on Jun 2016.
Vitaeris is a clinical-stage biopharmaceutical company focused on the development of the anti-interleukin-6 (IL-6) monoclonal antibody clazakizumab for chronic inflammatory diseases. This candidate has been licensed from Alder Pharmaceuticals and is in phase 1 trials for inflammatory diseases. The antibody has been specially engineered to remove antibody-dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). It also claims that in addition to Phase 1 safety studies, multinational Phase 2 clinical studies for the treatment of both rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have also been completed. Besides, the company is also pursuing innovative applications in chronic inflammatory diseases.
Vitaeris's top competitors include argenx, Escient Pharmaceuticals and Nimbus Therapeutics.
Vitaeris has 2 investors. Key investors include HBM Healthcare Investments, and CSL Behring.
Yes. Vitaeris was acquired by CSL Behring in June 2020.